These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31123786)

  • 1. Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D.
    Zwirner K; Hilke FJ; Demidov G; Socarras Fernandez J; Ossowski S; Gani C; Thorwarth D; Riess O; Zips D; Schroeder C; Welz S
    Strahlenther Onkol; 2019 Sep; 195(9):771-779. PubMed ID: 31123786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging-Genomic Study of Head and Neck Squamous Cell Carcinoma: Associations Between Radiomic Phenotypes and Genomic Mechanisms via Integration of The Cancer Genome Atlas and The Cancer Imaging Archive.
    Zhu Y; Mohamed ASR; Lai SY; Yang S; Kanwar A; Wei L; Kamal M; Sengupta S; Elhalawani H; Skinner H; Mackin DS; Shiao J; Messer J; Wong A; Ding Y; Zhang L; Court L; Ji Y; Fuller CD
    JCO Clin Cancer Inform; 2019 Feb; 3():1-9. PubMed ID: 30730765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival.
    Lin SC; Lin LH; Yu SY; Kao SY; Chang KW; Cheng HW; Liu CJ
    Carcinogenesis; 2018 Dec; 39(11):1320-1330. PubMed ID: 30102337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Proteomic Landscape of Growth Factor Signaling Networks Associated with
    Chen Z; Zhang C; Chen J; Wang D; Tu J; Van Waes C; Saba NF; Chen ZG; Chen Z
    Cancer Res; 2021 Sep; 81(17):4402-4416. PubMed ID: 34167951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
    Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
    Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Next-Generation Sequencing of Cancer-Related Genes in a Norwegian Patient Cohort With Head and Neck Squamous Cell Carcinoma Reveals Novel Actionable Mutations and Correlations With Pathological Parameters.
    Dongre HN; Haave H; Fromreide S; Erland FA; Moe SEE; Dhayalan SM; Riis RK; Sapkota D; Costea DE; Aarstad HJ; Vintermyr OK
    Front Oncol; 2021; 11():734134. PubMed ID: 34631566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients.
    Gao Y; Li Y; Ma G; Zhao G; Liu H
    Neoplasma; 2020 May; 67(3):636-643. PubMed ID: 32064880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between FAT1 mutation and overall survival in patients with human papillomavirus-negative head and neck squamous cell carcinoma.
    Kim KT; Kim BS; Kim JH
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E2021-9. PubMed ID: 26876381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma.
    Katsoulakis E; Yu Y; Apte AP; Leeman JE; Katabi N; Morris L; Deasy JO; Chan TA; Lee NY; Riaz N; Hatzoglou V; Oh JH
    Oral Oncol; 2020 Nov; 110():104877. PubMed ID: 32619927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of radiogenomics in esophageal cancer on clinical outcomes: A pilot study.
    Brancato V; Garbino N; Mannelli L; Aiello M; Salvatore M; Franzese M; Cavaliere C
    World J Gastroenterol; 2021 Sep; 27(36):6110-6127. PubMed ID: 34629823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
    Juhlin CC; Stenman A; Haglund F; Clark VE; Brown TC; Baranoski J; Bilguvar K; Goh G; Welander J; Svahn F; Rubinstein JC; Caramuta S; Yasuno K; Günel M; Bäckdahl M; Gimm O; Söderkvist P; Prasad ML; Korah R; Lifton RP; Carling T
    Genes Chromosomes Cancer; 2015 Sep; 54(9):542-54. PubMed ID: 26032282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming data scarcity in radiomics/radiogenomics using synthetic radiomic features.
    Ahmadian M; Bodalal Z; van der Hulst HJ; Vens C; Karssemakers LHE; Bogveradze N; Castagnoli F; Landolfi F; Hong EK; Gennaro N; Pizzi AD; Beets-Tan RGH; van den Brekel MWM; Castelijns JA
    Comput Biol Med; 2024 May; 174():108389. PubMed ID: 38593640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
    Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
    Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular landscape of head and neck cancer and implications for therapy.
    Farah CS
    Ann Transl Med; 2021 May; 9(10):915. PubMed ID: 34164549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI-based radiomic signature as predictive marker for patients with head and neck squamous cell carcinoma.
    Yuan Y; Ren J; Shi Y; Tao X
    Eur J Radiol; 2019 Aug; 117():193-198. PubMed ID: 31307647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.